Literature DB >> 7735232

Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice.

Y Sadzuka1, E Mochizuki, A Iwazaki, S Hirota, Y Takino.   

Abstract

We examined whether caffeine enhances the antitumor activity of adriamycin (ADR), in terms of prolonging survival in Ehrlich ascites carcinoma(ascites-type)-bearing mice. After administration of ADR at a dose of 0.5 mg/kg/d for 5d together with caffeine (100 mg/kg/d x 5 d), the survival period was increased by 39%. However, caffeine had little effect on this ADR induced-prolongation of survival following administration of ADR at 2.0 mg/kg/d for 4 d. Although a significant increase in ADR concentration in the ascites tumor was seen after administration of ADR at a dose of 0.5 mg/kg, caffeine failed to increase ADR concentration in the ascites tumor after administration of ADR at a dose of 2.0 mg/kg. The effect of caffeine thus appears to be due to its effect on the tumor distribution of ADR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7735232     DOI: 10.1248/bpb.18.159

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Spectral analysis of naturally occurring methylxanthines (theophylline, theobromine and caffeine) binding with DNA.

Authors:  Irudayam Maria Johnson; Halan Prakash; Jeyaguru Prathiba; Raghavachary Raghunathan; Raghunathan Malathi
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

3.  Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.

Authors:  Y Sadzuka; Y Egawa; T Sugiyama; H Sawanishi; K Miyamoto; T Sonobe
Journal:  Jpn J Cancer Res       Date:  2000-06

4.  1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin.

Authors:  Y Sadzuka; A Iwazaki; T Sugiyama; T Sawanishi; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1998-02

5.  Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity.

Authors:  Y Sadzuka; A Iwazaki; A Miyagishima; Y Nozawa; S Hirota
Journal:  Jpn J Cancer Res       Date:  1995-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.